Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The MRC Translational Immune Discovery Unit (MRC TIDU, previously called the MRC Human Immunology Unit) encompasses a unique community of leading specialist research programmes whose expertise combines to define the molecular pathogenesis of immune-mediated diseases.

Impaired immune function underpins many of the most prevalent human diseases. Susceptibility to immune disorders is variable between individuals for reasons that are unclear. Understanding immune variability is central to delivering precision medicine. We pioneer the direct study of the human immune system within lesional tissue and model systems using genomic, genome engineering, epigenome editing, single cell and computational tools to define immune disease pathogenesis. At present, new immunomodulatory drugs are introduced to the clinic with little molecular rationale for the target patient population or therapeutic combination. We lead in the discovery of immune pathogenesis to enable a more tailored approach.

To achieve our aims we have created a multidisciplinary grouping advancing the application of cutting-edge technologies to harness the power of the immune system to improve human health. This approach enables us to develop and implement novel technologies to better understand and treat immune-mediated inflammatory diseases.